Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 2/20 | 0.55 |
| ▸ | PDE2A | O00408 | 2/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.46 |
| ▸ | PLG | P00747 | 4/20 | 0.44 |
| ▸ | PLAU | P00749 | 4/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20982723 | 0.90 | CHEK2 (0.61) | CHEK2PDE2APDE3BPDE3AP2RY12 | |
| SCHEMBL20982736 | 0.85 | CHEK2 (0.57) | CHEK2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL20982498 | 0.81 | CHEK2 (0.60) | CHEK2PDE2APDE3BPDE3AP2RY12 | |
| SCHEMBL21017811 | 0.80 | CHEK2 (0.72) | CHEK2PDE2APDE3BPDE3AP2RY12 | |
| SCHEMBL14601532 | 0.79 | PDE3B (0.52) | CHEK2PDE2APDE3BPDE3AP2RY12 | |
| SCHEMBL1552348 | 0.79 | CHEK2 (0.67) | CHEK2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1552663 | 0.78 | CHEK2 (0.83) | CHEK2PLGPLAU | |
| SCHEMBL20982466 | 0.76 | CHEK2 (0.65) | CHEK2HDAC6PLGPLAU | |
| SCHEMBL21017805 | 0.76 | CHEK2 (0.67) | CHEK2PDE2APDE3BPDE3AP2RY12 | |
| SCHEMBL20982515 | 0.76 | CHEK2 (0.50) | CHEK2HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3710442-A2 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | The Scripps Research Institute (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-05-23 | — | — | US | disclosed |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | HNRNPH1, HNRNPH3, HNRNPUL2 | CHEK2 1163/4885PDE2A 3544/4885PDE3B 4067/4885 |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | HNRNPH1, HNRNPH3, HNRNPUL2 | CHEK2 1163/4885PDE2A 3544/4885PDE3B 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.